Brief: Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License
18/02/2026 23:18
Feb 18 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL AND BRIAPRO ENTER INTO ASSET PURCHASE AGREEMENT FOR EXCLUSIVE SOLUBLE CD80 LICENSE BRIACELL THERAPEUTICS CORP - BRIAPRO GAINS WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE SCD80 BRIACELL THERAPEUTICS CORP - BRIAPRO TO PAY 2% ROYALTIES TO UMBC UPON COMMERCIALIZATION BRIACELL THERAPEUTICS CORP - TO PROVIDE BRIAPRO UP TO $3 MILLION FOR RESEARCH AND DEVELOPMENT BRIACELL THERAPEUTICS CORP: AS PART OF TRANSACTION, BRIACELL WILL MAKE AVAILABLE TO BRIAPRO UP TO $3 MILLION TO FUND RESEARCH AND DEVELOPMENT EFFORT Source text: ID:nGNX7vF2SN Further company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study